← All trials
NCT00081731
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 1, 2004
- Primary completion
- Sep 1, 2013
- Completion date
- Sep 1, 2013
- First posted
- —
- Last posted
- —
- Enrollment
- 947
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- Harvard UniversityLead sponsor
- Rhode Island HospitalOverall official - principal investigator
- University of MinnesotaOverall official - principal investigator
- University of ToledoOverall official - principal investigator
- University of VirginiaOverall official - principal investigator
- Saint Luke's Health SystemOverall official - principal investigator
- Rhode Island HospitalStudy chair
- Harvard UniversityStudy chair
- Harvard UniversityOverall official - principal investigator
- Harvard UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.